COMMUNIQUÉS West-GlobeNewswire

Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform
19/03/2026
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product [...]
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
19/03/2026
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited [...]
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
19/03/2026
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
19/03/2026
- Purchase commitment is for a minimum of $1.475 million of Symvess product - DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing [...]
Evermore Expands Community Health Access in Ohio Through New Partnership with Discount Drug Mart
19/03/2026
BENTONVILLE, Ark., March 19, 2026 (GLOBE NEWSWIRE) -- evermore, the personalized health benefits platform transforming how people access the resources they need to live healthier lives, today announced a new retail [...]
CORRECTION: Lucia Gaitan, M.D., FACOG, First in Miami to Offer Cerene® Endometrial Cryotherapy for Women with Heavy Periods
19/03/2026
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on March 16, 2026 by Channel Medsystems, please note that in the seventh paragraph of the release, the contact details should be 305- [...]
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
19/03/2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS-driven tumors [...]
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
19/03/2026
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
19/03/2026
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX [...]
OKYO Pharma Announces Director Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
19/03/2026
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health. CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cylinder Health today announced the [...]
Passing of Genmab A/S’ Annual General Meeting
19/03/2026
Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Notice to convene Evaxion’s Annual General Meeting
19/03/2026
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General [...]
Diadia Launches AI Platform to Finally Give Women Answers to "Unexplained" Health Problems
19/03/2026
Former Google and Reddit AI scientist builds tool to decode genetic clues standard medicine dismisses as "normal" NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- For women suffering from unexplained infertility, crushing [...]
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
19/03/2026
NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S [...]
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
19/03/2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
19/03/2026
New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with [...]
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
19/03/2026
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, [...]
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
19/03/2026
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The [...]

Pages